{"id":7275,"date":"2021-12-16T07:20:09","date_gmt":"2021-12-16T12:20:09","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/enfuvirtide-enfuvirtide-acetat-cas-159519-65-0-fuer-anti-hiv\/"},"modified":"2021-12-16T07:20:09","modified_gmt":"2021-12-16T12:20:09","slug":"enfuvirtide-enfuvirtide-acetat-cas-159519-65-0-fuer-anti-hiv","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/de\/product\/enfuvirtide-enfuvirtide-acetat-cas-159519-65-0-fuer-anti-hiv\/","title":{"rendered":"Enfuvirtide\/Enfuvirtide Acetat CAS 159519-65-0 f\u00fcr Anti-HIV"},"content":{"rendered":"

Enfuvirtide\/Enfuvirtide Acetat CAS 159519-65-0 f\u00fcr Anti-HIV<\/strong><\/h2>\n

Produktname: Enfuvirtid
\nSequenz: Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys< &>-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
\nSynonyme: Enfuvirtide; T-2;Enfuvirtidacetat (T-20);ENFUVIRTIDE (T-20) 98+%;Enfurvitid (T-20);Pentafusid;Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile -Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn -Trp-Phe-NH{2};Enfuvirtide;Aids059486
\nCAS: 159519-65-0
\nMF: C204H301N51O64
\nMW: 4491.92
\nEINECS: 641-385-0
\nProduktkategorien : Proteine;Peptid
\nMol File: 159519-65-0.mol<\/p>\n

Es ist ein synthetischer Peptid-Inhibitor der HIV-Fusion, der an das virale H\u00fcllglykoprotein binden und die f\u00fcr das Virus notwendigen Konformations\u00e4nderungen verhindern kann mit der Zellmembran zu fusionieren, wodurch die Replikation von HIV-1 gehemmt wird. Das Enfevir-Peptid leitet sich von einer nat\u00fcrlich vorkommenden Aminos\u00e4uresequenz in der HR2-Dom\u00e4ne von gp41 ab. Durch die Simulation der Aktivit\u00e4t der HR2-Dom\u00e4ne und die kompetitive Bindung an die HR1-Dom\u00e4ne von gp41 verhindert das Enfevir-Peptid die Interaktion zwischen HR1 und HR2 sowie Ver\u00e4nderungen in der Konfiguration von Gp41 und verhindert so die Fusion des Virus mit Wirtszellen.<\/p>\n

Enfuvirtide ist das erste einer neuen Klasse von HIV-Therapeutika, das das Eindringen von HIV-1 durch Hemmung der Fusion von Virus- und Zellmembranen verhindert. Es bindet an das erste Heptad-Repeat (HR1) in der ghe gp41-Untereinheit des viralen H\u00fcllglykoproteins und verhindert die f\u00fcr die Fusion mit Zellmembranen erforderlichen Konformations\u00e4nderungen, was einen neuen Mechanismus darstellt. Es ist ein potenter Inhibitor dieser Bindung mit einem IC50 in Labor- und Prim\u00e4risolaten (HIV-1-Kladen A\u2013G) im Bereich von 4 bis 280 nM (18\u20131260 ng\/ml), hat jedoch praktisch keine Aktivit\u00e4t gegen HIV-2. Aufgrund seines einzigartigen Mechanismus zeigt es keine Kreuzresistenz gegen\u00fcber NRTI, NNRTI und PIs. Es wird durch chemische Synthese hergestellt, wobei eine Kombination aus L\u00f6sungs- und Festphasenschritten verwendet wird. Die Festphasenschritte nutzen den fmoc-Schutz und das s\u00e4ureempfindliche 2-Chlortritylchlorid-Harz, um Peptide mit L\u00e4ngen im Bereich von neun bis sechzehn Aminos\u00e4uren herzustellen. <\/p>\n

Enfuvirtid\/ Enfuvirtide Acetate CAS 159519-65-0 Chemische Eigenschaften<\/strong>
\nLagertemp. -20\u00b0C
\nPulverform
\nFarbe wei\u00df bis cremefarben<\/p>\n

Verwendungen von Enfuvirtide\/Enfuvirtide Acetate CAS 159519-65-0<\/strong>
\nWird in Kombination mit Reverse-Transkriptase-Medikamenten f\u00fcr den Menschen verwendet Infektion mit dem Immunschw\u00e4chevirus (HIV).<\/p>\n","protected":false},"excerpt":{"rendered":"

Produktname: Enfuvirtide
\nCAS: 159519-65-0
\nMF: C204H301N51O64
\nMW: 4491.92
\nEINECS: 641-385-0
\nMol File: 159519-65-0.mol<\/p>\n","protected":false},"featured_media":2123,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[522],"product_tag":[2509],"class_list":{"0":"post-7275","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-andere-peptide","7":"product_tag-enfuvirtide-enfuvirtide-acetate-cas-159519-65-0-for-anti-hiv-de","8":"desktop-align-left","9":"tablet-align-left","10":"mobile-align-left","12":"first","13":"instock","14":"shipping-taxable","15":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product\/7275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/comments?post=7275"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/media\/2123"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/media?parent=7275"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product_brand?post=7275"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product_cat?post=7275"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/de\/wp-json\/wp\/v2\/product_tag?post=7275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}